Medical devices, healthcare technology and the business of care
PMA approval · P150033

MEDTRONIC MICRA TRANSCATHETER PACEMAKER SYSTEM

Medtronic, Inc. · Decision date Apr 6, 2016

MEDTECHLEDGER EXPLANATIONP150033

What did the FDA approve?

FDA approved Medtronic's Micra Transcatheter Pacemaker System, Pacemaker Model MC1VR01 with Programmer Application Software model SW022 Version 1.1, on April 6, 2016. The approval covers the leadless pacemaker for patients with symptomatic paroxysmal or permanent high-grade AV block in the presence of atrial fibrillation, or in the absence of AF when atrial lead placement is considered difficult, high risk, or not deemed necessary for effective therapy.

The indication also includes symptomatic bradycardia-tachycardia syndrome or sinus node dysfunction, including sinus bradycardia or sinus pauses, as an alternative to atrial or dual chamber pacing under the same atrial lead placement conditions. Rate-responsive pacing is indicated to provide increased heart rate appropriate to increasing levels of activity. The statement reports the device's intended use; it does not independently establish safety or clinical effectiveness.

FDA approval order statement

Approval for the Micra Transcatheter Pacemaker System (Pacemaker Model MC1VR01 and Programmer Application Software model SW022 Version 1.1). This device is indicated for use in patients who have experienced one or more of the following conditions: symptomatic paroxysmal or permanent high-grade AV block in the presence of AF symptomatic paroxysmal or permanent high-grade AV block in the absence of AF, as an alternative to dual chamber pacing, when atrial lead placement is considered difficult, high risk, or not deemed necessary for effective therapy symptomatic bradycardia-tachycardia syndrome or sinus node dysfunction (sinus bradycardia or sinus pauses), as an alternative to atrial or dual chamber pacing, when atrial lead placement is considered difficult, high risk, or not deemed necessary for effective therapyRate-responsive pacing is indicated to provide increased heart rate appropriate to increasing levels of activity.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Apr 6, 2016

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150033
Regulatory pathway
Premarket approval application
Product code
PNJ
Decision code
APPR
Decision date
Apr 6, 2016
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Leadless pacemaker.

Product code
PNJ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P150033 received

    Application receipt date recorded by FDA.

  2. P150033 · FDA decision

    APPR

  3. P150033/S230 · Related supplement

    Micra Functional Testing on pNGHT and NGHT

Timeline entries are records held by MedtechLedger for P150033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150033

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementSep 8, 2026FDA

Explore the linked device profile

Other records with product code PNJ

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA supplementOct 21, 2026FDA
ABBOTT MEDICALPMA approvalMar 31, 2022FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records